UCB

UCB is a global biopharmaceutical leader founded in 1928, specializing in the discovery and commercialization of innovative medicines for severe neurological and autoimmune conditions. The company maintains a robust therapeutic focus on neurology, addressing epilepsy and Parkinson's disease, alongside immunology treatments for rheumatoid arthritis, Crohn's disease, psoriasis, and axial spondyloarthritis. By integrating patient and caregiver insights into its R&D pipeline, UCB ensures that scientific innovation aligns with health equity and sustainable value creation.

Operating across more than 40 countries, UCB manages a complex global footprint with 5,000-10,000 employees. The organization maintains a significant operational presence in the United States, with its U.S. headquarters located in Smyrna, Georgia, supporting clinical development and policy functions. Learn about UCB's global headquarters for comprehensive details regarding their international infrastructure and geographic presence. The company leverages its extensive network to drive biopharmaceutical advancements and maintain a competitive edge in the global healthcare market.

UCB’s marketed product portfolio includes key therapeutic assets such as Cimzia, Vimpat, Keppra, Briviact, Neupro, Bimzelx, Evenity, and Fintepla. These innovative medicines represent the company's commitment to addressing unmet medical needs through advanced scientific research. Meet UCB's team to learn about the leadership and organizational structure driving these clinical breakthroughs. Through its focus on patient-centric solutions and high-impact pharmaceutical development, UCB continues to solidify its position as a major player in the biopharmaceutical industry.